MINNEAPOLIS, Jan. 12, 2023 (GLOBE NEWSWIRE) — CVRx, Inc. (“CVRx”), a commercial-stage medical technology company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients suffering from cardiovascular disease , announced today that it plans to release its fourth quarter and full year 2022 financial and operating results after the market close on Thursday, January 26, 2023. The company will host a conference call to review its host results.

The conference call will be webcast live in listen-only mode at https://edge.media-server.com/mmc/p/d5cu7e7x.To listen to the conference call on your phone, participants can register for the conference call here. Although not required, it is recommended that you attend 10 minutes prior to the start of the event.

About CVRx, Inc.

CVRx is focused on the development and commercialization of Barostim™, the first FDA-cleared medical technology that uses neuromodulation to improve symptoms in heart failure patients. Barostim is an implantable device that delivers electrical impulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate the body’s baroreflex, which in turn triggers an autonomic response to the heart. The therapy aims to restore the balance of the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim has received FDA Breakthrough Device designation and is FDA cleared for use in heart failure patients in the United States. It has also received the CE mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.

Investor contact:

Mark Klausner or Mike Vallie
ICR Westwicke
443-213-0501
ir@cvrx.com

Media contact:

Erich Sandowal
Finnish partners
212-867-1762
erich.sandoval@finnpartners.com